|
1.
|
Epstein MA, Barr YM and Achong BG: Virus
particles in cultured lymphoblasts from Burkitt’s lymphoma. Lancet.
15:702–703. 1964.PubMed/NCBI
|
|
2.
|
Caldwell RG, Wilson JB, Anderson SJ and
Longnecker R: Epstein-Barr virus LMP2A drives B cell development
and survival in the absence of normal B cell receptor signals.
Immunity. 9:405–411. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Henderson S, Huen D, Rowe M, Dawson C,
Johnson G and Rickinson A: Epstein-Barr virus-coded BHRF1 protein,
a viral homologue of Bcl-2, protects human B cells from programmed
cell death. Proc Natl Acad Sci USA. 90:8479–8483. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Rathmell JC, Townsend SE, Xu JC, Flavell
RA and Goodnow CC: Expansion or elimination of B cells in vivo:
dual roles for CD40-and Fas (CD95)-ligands modulated by the B cell
antigen receptor. Cell. 87:319–329. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Rathmell JC, Cooke MP, Ho WY, Grein J,
Townsend SE, Davis mM and Goodnow CC: CD95 (Fas)-dependent
elimination of self-reactive B cells upon interaction with
CD4+ T cells. Nature. 376:181–184. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Lagresle C, Mondière P, Bella C, Krammer
PH and Defrance T: Concurrent engagement of CD40 and the antigen
receptor protects naive and memory human B cells from
APO-1/Fas-mediated apoptosis. J Exp Med. 183:1377–1388. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Jacobson BA, Panka DJ, Nguyen KA, Erikson
J, Abbas AK and Marshak-Rothstein A: Anatomy of autoantibody
production: dominant localization of antibody-producing cells to T
cell zones in Fas-deficient mice. Immunity. 3:509–519. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Arcipowski KM, Stunz LL, Graham JP, Kraus
ZJ, Vanden Bush TJ and Bishop GA: Molecular mechanisms of
TNFR-associated factor 6 (TRAF6) utilization by the oncogenic viral
mimic of CD40, latent membrane protein 1 (LMP1). J Biol Chem.
286:9948–9955. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Arcipowski KM and Bishop GA: Roles of the
kinase TAK1 in TRAF6-dependent signaling by CD40 and its oncogenic
viral mimic, LMP1. PLoS One. 7:e424782012. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Graham JP, Arcipowski KM and Bishop GA:
Differential B lymphocyte regulation by CD40 and its viral mimic,
latent membrane protein 1. Immunol Rev. 237:226–248. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Mongini PK, Tolani S, Fattah RJ and Inman
JK: Antigen receptor triggered upregulation of CD86 and CD80 in
human B cells: augmenting role of the CD21/CD19 co-stimulatory
complex and IL-4. Cell Immunol. 216:50–64. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Evans DE, Munks MW, Purkerson JM and
Parker DC: Resting B lymphocytes as APC for naive T lymphocytes:
dependence on CD40 ligand/CD40. J Immunol. 164:688–697. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Clatza A, Bonifaz LC, Vignali DA and
Moreno J: CD40-induced aggregation of MHC class II and CD80 on the
cell surface leads to an early enhancement in antigen presentation.
J Immunol. 171:6478–6487. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Bluestone JA: New perspectives of
CD28-B7-mediated T cell costimulation. Immunity. 2:555–559. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Jirapongsananuruk O, Hofer MF, Trumble AE,
Norris DA and Leung DY: Enhanced expression of B7.2 (CD86) in
patients with atopic dermatitis: a potential role in the modulation
of IgE synthesis. J Immunol. 160:4622–4627. 1998.PubMed/NCBI
|
|
16.
|
Lenschow DJ, Walunas TL and Bluestone JA:
CD28/B7 system of T cell costimulation. Annu Rev Immunol.
14:233–258. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Rathmell JC, Fournier S, Weintraub BC,
Allison JP and Goodnow CC: Repression of B7.2 on self-reactive B
cells is essential to prevent proliferation and allow Fas-mediated
deletion by CD4(+) T cells. J Exp Med. 17:651–659. 1998.PubMed/NCBI
|
|
18.
|
Ikemizu S, Gilbert RJ, Fennelly JA,
Collins AV, Harlos K, Jones EY, Stuart DI and Davis SJ: Structure
and dimerization of a soluble form of B7-1. Immunity. 12:51–60.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Bajorath J, Peach RJ and Linsley PS:
Immunoglobulin fold characteristics of B7-1 (CD80) and B7-2 (CD86).
Protein Sci. 3:2148–2150. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Heath AW, Chang R, Harada N, Argumedo LS,
Gordon J, Hannum C, Campell D, Shanafelt AB, Clark EA, Torres R and
Howard M: Antibodies to murine CD40 stimulate normal B lymphocytes
but inhibit proliferation of B lymphoma cells. Cell Immunol.
152:468–480. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Borriello F, Sethna MP, Boyd SD,
Schweitzer AN, Tivol EA, Jacoby D, Strom TB, Simpson EM, Freeman GJ
and Sharpe AH: B7-1 and B7-2 have overlapping, critical roles in
immunoglobulin class switching and germinal center formation.
Immunity. 6:303–331. 1997. View Article : Google Scholar
|
|
22.
|
Suvas S, Singh V, Sahdev S, Vohra H and
Agrewala JN: Distinct role of CD80 and CD86 in the regulation of
the activation of B cell and B cell lymphoma. J Biol Chem.
277:7766–7775. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Kim YS, Park GB, Lee HK, Song H, Choi IH,
Lee WJ and Hur DY: Cross-linking of B7-H1 on EBV-transformed B
cells induces apoptosis through reactive oxygen species production,
JNK signaling activation, and fasL expression. J Immunol.
181:6158–6169. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Song H, Park G, Kim YS, Hur I, Kim H, Ryu
JW, Lee HK, Cho DH, Choi IH, Lee WJ and Hur DY: B7-H4 reverse
signaling induces the apoptosis of EBV-transformed B cells through
Fas ligand up-regulation. Cancer Lett. 266:227–237. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Park GB, Song H, Kim YS, Sung M, Ryu JW,
Lee HK, Cho DH, Kim D, Lee WJ and Hur DY: Cell cycle arrest induced
by engagement of B7-H4 on Epstein-Barr virus-positive B-cell
lymphoma cell lines. Immunology. 128:360–368. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Andreyev AY, Kushnareva YE and Starkov AA:
Mitochondrial metabolism of reactive oxygen species. Biochemistry.
70:200–214. 2005.PubMed/NCBI
|
|
27.
|
Saelens X, Festjens N, Vande Walle L, van
Gurp M, van Loo G and Vandenabeele P: Toxic proteins released from
mitochondria in cell death. Oncogene. 23:2861–2874. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Cregan SP, Dawson VL and Slack RS: Role of
AIF in caspase-dependent and caspase-independent cell death.
Oncogene. 23:2785–2796. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Bornkamm GW and Hammerschmidt W: Molecular
virology of Epstein-Barr virus. Phil Trans R Soc Lond B Biol Sci.
356:437–459. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Kempkes B, Spitkovsky D, Jansen-Durr P,
Ellwart GW, Kremmer E, Delecluse HJ, Rottenberger C, Bornkamm GW
and Hammerschmidt W: B cell proliferation and induction of early
G1-regulating proteins by Epstein-Barr virus mutants conditional
for EBNA2. EMBO J. 14:88–96. 1995.PubMed/NCBI
|
|
31.
|
Yamada S, Shinozaki K and Agematsu K:
Involvement of CD27/CD70 interactions in antigen-specific cytotoxic
T-lymphocyte (CTL) activity by perforin-mediated cytotoxicity. Clin
Exp Immunol. 130:424–430. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Gordon J, Millsum MJ, Guy GR and Ledbetter
JA: Resting B lymphocytes can be triggered directly through the
CDw40 (Bp50) antigen. A comparison with IL-4-mediated signaling. J
Immunol. 140:1425–1430. 1988.PubMed/NCBI
|
|
33.
|
Goldstein MD and Watts TH: Identification
of distinct domains in CD40 involved in B7-1 induction or growth
inhibition. J Immunol. 157:2837–2843. 1996.PubMed/NCBI
|
|
34.
|
Nakajima A, Kodama T, Morimoto S, Azuma M,
Takeda K, Oshima H, Yoshino S, Yagita H and Okumura K: Antitumor
effect of CD40 ligand: elicitation of local and systemic antitumor
responses by IL-12 and B7. J Immunol. 161:1901–1907.
1998.PubMed/NCBI
|
|
35.
|
Bergamo A, Bataille R and
Pellat-Deceunynck C: CD40 and CD95 induce programmed cell death in
the human myeloma cell line XG2. Br J Haematol. 97:652–655. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Snow AL, Chen LJ, Nepomuceno RR, Krams SM,
Esquivel CO and Martinez OM: Resistance to Fas-mediated apoptosis
in EBV-infected B cell lymphomas is due to defects in the proximal
Fas signaling pathway. J Immunol. 167:5404–5411. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Tepper CG and Seldin MF: Modulation of
caspase-8 and FLICE-inhibitory protein expression as a potential
mechanism of Epstein-Barr virus tumorigenesis in Burkitt’s
lymphoma. Blood. 94:1727–1737. 1999.PubMed/NCBI
|
|
38.
|
Le Clorennec C, Youlyouz-Marfak I,
Adriaenssens E, Coll J, Bornkamm GW and Feuillard J: EBV latency
III immortalization program sensitizes B cells to induction of
CD95-mediated apoptosis via LMP1: role of NF-kappaB, STAT1, and
p53. Blood. 107:2070–2078. 2006.PubMed/NCBI
|
|
39.
|
Durandy A, Le Deist F, Emile JF, Debatin K
and Fischer A: Sensitivity of Epstein-Barr virus-induced B cell
tumor to apoptosis mediated by anti- CD95/Apo-1/fas antibody. Eur J
Immunol. 27:538–543. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Li-Weber M and Krammer PH: Function and
regulation of the CD95 (APO-1/Fas) ligand in the immune system.
Semin Immunol. 15:145–157. 2003. View Article : Google Scholar : PubMed/NCBI
|
